Stock Market Reviews

Read and share opinions on BMRN (BioMarin Pharmaceutical Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

Latest News

• BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know
  Dec 23, 2025
• Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition
  Dec 23, 2025
• A $4.8 Billion Reason to Buy BioMarin Stock Today
  Dec 22, 2025
• BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
  Dec 22, 2025
• BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus
  Dec 20, 2025
• Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
  Dec 19, 2025
• BioMarin Pharmaceutical to Acquire Amicus Therapeutics in $4.8 Billion Deal
  Dec 19, 2025
• Update: BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 Billion; Shares Jump
  Dec 19, 2025

BMRN News

• Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio?
  These ten large-cap stocks were top performers last week. Are they a part of your portfolio? Rocket Lab Corporation (NASDAQ:RKLB) gained 15.5% this week after the company announced it launched its 21st Electron rocket of the year to deploy the latest satellite to space for multi-launch customer Institute for Q-shu Pioneers of Space. Also, Needham analyst Ryan Koontz maintained a Buy rating, raising the price forecast from $63 to $90. Lumentum Holdings Inc. (NASDAQ:LITE) gained 14.76% this week B
  Dec 30, 2025
• Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
  Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower on Friday, with the venerable S&P 500 taking early bows as it hit a fresh all-time high, joining the Dow Jones Industrial Average ... Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
  Dec 29, 2025
• Spruce Biosciences initiated with an Outperform at Oppenheimer
  Oppenheimer initiated coverage of Spruce Biosciences (SPRB) with an Outperform rating and $283 price target. Further to FDA’s confirmation that existing and what the firm views as “compelling” clinical biomarker data could drive accelerated approval, recent Breakthrough Therapy designation bolsters the firm’s conviction ahead of next year’s anticipated approval for Sanfilippo type B syndrome, the analyst tells investors. The firm, which sees “considerable upside for this underappreciated story,”
  Dec 24, 2025
• Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition
  We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. BioMarin Pharmaceuticals Inc. stands second among the most promising stocks. TheFly reported on December 19 that BMRN announced it will acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion, paying $14.50 per share. The deal strengthens BMRN’s […]
  Dec 23, 2025
• BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know
  Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the afternoon session after the stock's positive momentum continued as the company agreed to acquire Amicus Therapeutics for a total equity value of about $4.8 billion, a move expected to boost future growth. BioMarin's President and CEO, Alexander Hardy, said the transaction was expected to accelerate the company's revenue growth and strengthen its financial outlook. The deal was viewed positively by analysts, with T
  Dec 23, 2025
• BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
  BMRN agrees to acquire FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to its portfolio.
  Dec 22, 2025
• A $4.8 Billion Reason to Buy BioMarin Stock Today
  BioMarin stock soars as the biotech firm announces a $4.8 billion acquisition of Amicus Therapeutics. The transaction could push BMRN shares even higher in 2026.
  Dec 22, 2025
• BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push
  The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially supporting the company’s revenue stream.
  Dec 22, 2025
• BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus
  We recently published 10 Firms in the Limelight. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best performers on Friday. BioMarin Pharmaceutical extended its winning streak to a third straight day on Friday, surging 17.71 percent to finish at $61.15 apiece, as investors took heart from its expansion initiatives following the acquisition of Amicus Therapeutics […]
  Dec 20, 2025
• Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger
  We recently published 10 Firms in the Limelight. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday. Amicus Therapeutics soared to a new 52-week high on Friday, jumping 30.21 percent to close at $14.18 apiece as investors gobbled up shares following announcements that it would merge with Biomarin Pharmaceutical for nearly $5 […]
  Dec 20, 2025
• Sector Update: Health Care Stocks Rise Late Afternoon
  Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t
  Dec 19, 2025
• Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play
  A high-stakes buyout could supercharge BioMarin's pipeline and shake up the rare-disease drug landscape by 2030.
  Dec 19, 2025
• Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals
  All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige
  Dec 19, 2025
• BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
  BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The agreement has been unanimously approved by the Boards of Directors of both companies and Amicus' Board of Directors unanimously recommended that Amicus' stockholders vote to adopt the agreement. The transaction is expecte
  Dec 19, 2025
• Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
  Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 19% in the afternoon session after the company announced it agreed to acquire Amicus Therapeutics for approximately $4.8 billion in an all-cash deal.
  Dec 19, 2025
• BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.
  It’s the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
  Dec 19, 2025
• BioMarin to buy rare disease drugmaker Amicus for $4.8B
  Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies that generated nearly $450 million over the first nine months of this year.
  Dec 19, 2025
• BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus
  BioMarin said Friday it will acquire Amicus Therapeutics for $4.8 billion in a deal that adds two rare disease drugs to its portfolio.
  Dec 19, 2025
• BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 billion
  BioMarin Pharmaceutical (BMRN) has agreed to acquire Amicus Therapeutics (FOLD) for $14.50 per share
  Dec 19, 2025
• Update: BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 Billion; Shares Jump
  (Updates with share price movement in headline and last paragraph). BioMarin Pharmaceutical (BMRN
  Dec 19, 2025
• BioMarin Pharmaceutical to Acquire Amicus Therapeutics in $4.8 Billion Deal
  BioMarin Pharmaceutical (BMRN) on Friday agreed to acquire Amicus Therapeutics (FOLD) in an all-cash
  Dec 19, 2025
• BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion
  BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.
  Dec 19, 2025
• Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle
  ↗️ Oracle (ORCL): TikTok parent Bytedance formally agreed to form a new U.S. joint venture that will be 50% held by an investor consortium that includes Oracle. Shares jumped 6.6%. ↗️ CoreWeave (CRWV): Shares in the data-center operator jumped, extending a rebound that follows punishing declines.
  Dec 19, 2025
• 1 Oversold Stock Primed to Rebound and 2 That Underwhelm
  The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
  Dec 16, 2025
• Do Options Traders Know Something About BMRN Stock We Don't?
  Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.
  Dec 15, 2025
• Can BioMarin (BMRN) Turn Margin Ambitions Into Strength Amid Rising Rare-Disease Competition?
  Earlier this month, BioMarin Pharmaceutical updated investors on its US$500 million cost transformation program, now about two-thirds complete, and outlined a target of reaching a 40% non-GAAP operating margin next year while sharpening its focus on genetically defined rare conditions. At the same time, an analyst downgrade highlighted concerns about rising competition in achondroplasia and gaps in BioMarin’s pipeline, even as the company pursues margin improvement, restructurings, and the...
  Dec 12, 2025
• Is The Market Mispricing BioMarin After Its Multi Year Share Price Slump In 2025
  Wondering if BioMarin Pharmaceutical is starting to look like a bargain after a rough stretch, or if the market sees trouble that is not obvious yet? This breakdown will walk you through what the current price is really implying. Despite trading around $52.99, the stock is down about 1.5% over the last week, 3.5% over the last month, and roughly 20% year to date, extending a multi year slide of about 51.2% over 3 years and 41.3% over 5 years. Those declines have come alongside a wave of...
  Dec 12, 2025
• BioMarin Pharmaceutical (BMRN) Valuation Check After This Year’s 20% Share Price Pullback
  BioMarin Pharmaceutical (BMRN) has quietly slipped about 20% this year, which is drawing more attention from investors than any single headline. With revenue and net income still growing, the pullback raises a simple question: is this weakness justified? See our latest analysis for BioMarin Pharmaceutical. That slide reflects a broader loss of confidence, with the share price down about 20% year to date and the three year total shareholder return dragging more than 50%. At the same time,...
  Dec 12, 2025
• Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price Target to $60, Citing Valuation and Competitive Challenges
  Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best biotech stocks to buy according to Wall Street analysts. On November 18, BioMarin Pharmaceutical (NASDAQ:BMRN) presented at the Jefferies London Healthcare Conference, where CEO Alexander outlined progress on the company’s $500 million cost transformation program, now about two-thirds complete, and announced a goal of reaching a […]
  Dec 11, 2025
• BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink
  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the cheap healthcare stocks to buy heading into 2026. As reported by TheFly, Leerink reduced the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $60 from $82 and downgraded it to Market Perform from Outperform on December 3. According to the analyst, the actions taken by new leadership, including […]
  Dec 10, 2025
• BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory
  We came across a bullish thesis on BioMarin Pharmaceutical Inc. on Value investing subreddit by BearWithMeGM. In this article, we will summarize the bulls’ thesis on BMRN. BioMarin Pharmaceutical Inc.’s share was trading at $53.89 as of December 2nd. BMRN’s trailing and forward P/E were 20.45 and 11.19 respectively according to Yahoo Finance. BioMarin Pharmaceutical Inc., a biotechnology […]
  Dec 4, 2025
• Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?
  Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 3, 2025
• Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report?
  Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Nov 27, 2025
• BioMarin Pharmaceutical (BMRN): Evaluating Valuation After Raised Guidance on Revenue Strength
  BioMarin Pharmaceutical (BMRN) just posted quarterly revenues rising 4% to $776 million, matching Wall Street views. Growth was fueled by strong performance in PALYNZIQ and VOXZOGO, and this prompted BioMarin to raise its full-year outlook more than its competitors. See our latest analysis for BioMarin Pharmaceutical. BioMarin’s raised outlook has drawn fresh investor attention, but shares are still down nearly 17% year-to-date and have delivered a -15% total shareholder return over the past...
  Nov 27, 2025
• 2 Reasons to Like BMRN and 1 to Stay Skeptical
  BioMarin Pharmaceutical currently trades at $55.56 per share and has shown little upside over the past six months, posting a small loss of 4.4%. The stock also fell short of the S&P 500’s 11.5% gain during that period.
  Nov 25, 2025
• Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks
  The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with BioMarin Pharmaceutical (NASDAQ:BMRN).
  Nov 24, 2025
• BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?
  Over the past six months, BioMarin Pharmaceutical’s stock price fell to $51.76. Shareholders have lost 11.5% of their capital, which is disappointing considering the S&P 500 has climbed by 13.7%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
  Nov 21, 2025
• AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025
• Examining BioMarin Stock After Pipeline Advances and Recent Price Rebound in 2025
  Ever wondered if BioMarin Pharmaceutical is really worth its current price? Let's break down what the market is seeing and whether there might be untapped value here. After a rollercoaster year, BioMarin’s stock is up 4.6% this past week and 3.3% over the past month, though it's still down more than 17% for the last year. This reflects both renewed optimism and lingering caution. Much of this recent movement follows news about advances in their pipeline therapies and expanded regulatory...
  Nov 14, 2025
• 1 Safe-and-Steady Stock on Our Watchlist and 2 We Question
  A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
  Nov 13, 2025
• Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
  Nov 11, 2025
• BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
  BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England in London.
  Nov 11, 2025
• 3 Cash-Producing Stocks with Promising Prospects
  Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.
  Nov 10, 2025
• J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN)
  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best stocks to buy with over 50% upside potential. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported its fiscal Q3 2025 results on October 27. Total revenues for the quarter were $776 million, reflecting a 4% growth compared to the prior year period. This growth was driven by strong revenue […]
  Nov 4, 2025
• BioMarin (BMRN): Valuation Insights After Revenue Upside and PALYNZIQ Expansion News
  BioMarin Pharmaceutical (BMRN) caught investor attention after the company reported steady revenue growth for Q3 2025 and raised its full-year guidance. This reflects commercial momentum in key therapeutic areas. The FDA’s acceptance of a supplemental Biologics License Application for PALYNZIQ to include adolescents with PKU also marks an important regulatory milestone. This could further expand BioMarin’s addressable market. See our latest analysis for BioMarin Pharmaceutical. BioMarin...
  Nov 4, 2025
• The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call
  BioMarin Pharmaceutical’s third quarter results reflected steady top-line growth, with management highlighting enzyme therapies and the Skeletal Conditions business as main contributors. CEO Alexander Hardy credited global demand for therapies like VOXZOGO and PALYNZIQ, noting, “These strong results are driven by the performance of our global enzyme therapies and Skeletal Conditions business units as we deliver for patients around the world.” The company’s operating margins declined due to highe
  Nov 3, 2025
• Pulmonary Emphysema Market Set to Expand by 2034 with Rising COPD Prevalence and Therapeutic Innovation | DelveInsight
  The pulmonary emphysema market is poised for steady growth driven by rising COPD prevalence, an aging global population, and greater diagnostic awareness. Advances in inhaled therapies, targeted biologics, and minimally invasive interventions are expanding treatment options and market share. Additionally, the launch of therapies such as Tanimilast (CHF6001) (Chiesi Farmaceutici S.p.A.), SAR-447537 (Sanofi), Solrikitug (Uniquity Bio), PBF-680 (Palobiofarma), BMN-349 (BioMarin Pharmaceutical), and
  Nov 3, 2025
• Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN)
  ​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Best Beaten Down Growth Stocks to Buy According to Analysts. On October 19, Sean Laaman from Morgan Stanley maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a price target of $104. ​The analyst likes the company’s market position and growth potential. He noted that the […]
  Nov 1, 2025
• BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025
  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Stocks to Buy with Exponential Growth Heading into 2026. On October 27, the company announced financial results for Q3 2025 and highlighted the contributions from its Enzyme Therapies and Skeletal Conditions business units to date this year, thanks to over 20% revenue growth from PALYNZIQ and VOXZOGO. BioMarin […]
  Oct 31, 2025
• BioMarin Pharmaceutical Inc. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
  Shareholders might have noticed that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) filed its third-quarter result this...
  Oct 30, 2025
• BioMarin Pharmaceutical (BMRN) Margin Gains Reinforce Bullish Narratives Despite Slower Revenue Outlook
  BioMarin Pharmaceutical (BMRN) delivered earnings growth of 61.5% over the past year, outpacing its previous five-year annual earnings decline of 8.5%. Net profit margins also improved, rising to 16.8% from 11.7% a year earlier. Forecasts call for earnings to expand 21.3% per year, ahead of the US market's 15.6% pace. With profitability accelerating and margins moving higher, investors are focusing on an earnings story marked by growth and improved value signals. See our full analysis for...
  Oct 29, 2025
• FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
  BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's PALYNZIQ® (pegvaliase-pqpz) supplemental Biologics License Application (sBLA) to expand treatment to include adolescents aged 12-17 with phenylketonuria (PKU). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of Feb. 28, 2026.
  Oct 29, 2025
• BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
  BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.
  Oct 28, 2025
• Does BioMarin’s Share Price Decline Signal an Opportunity in 2025?
  If you have been watching BioMarin Pharmaceutical’s stock chart lately, you are probably wondering if now is the moment to act: hold tight, make a move, or look elsewhere altogether. The company’s share price has been on a bit of a roller coaster, down 0.8% over the past week, off 2.2% for the last month, and showing a striking 20.8% decline year-to-date. Even more noticeable, the stock has fallen nearly 25% over the last year and sits far below its highs from previous years. This downward...
  Oct 28, 2025
• Why is BioMarin Pharmaceutical (BMRN) One of the Most Profitable Biotech Stocks to Buy?
  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on October 21 and set a price target of $90. Similarly, Morgan Stanley analyst Sean Laaman also maintained a bullish stance on the stock on October 19, assigning it a […]
  Oct 28, 2025
• Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today
  Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 4.5% in the morning session after the company reported third-quarter earnings, which featured a significant earnings miss but a slight increase in its full-year revenue forecast.
  Oct 28, 2025
• BioMarin’s ROCTAVIAN Exit and Higher Guidance Could Be a Game Changer for BMRN
  BioMarin Pharmaceutical recently reported its third-quarter 2025 financial results, showing revenues of US$776.13 million, a rise from the previous year, but also a net loss of US$30.74 million, compared to a profit a year earlier. An important development was the company’s decision to raise its full-year revenue guidance and announce plans to divest the gene therapy ROCTAVIAN, signaling a sharpened focus on its core growth areas such as enzyme therapies and skeletal condition...
  Oct 28, 2025
• Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday
  Although the company recorded higher sales overall, it's decided to divest one of its products.
  Oct 28, 2025

BMRN Reviews

• VolatilityViper

  Dec 31, 2025

  $BMRN Another overhyped biotech? Hope you enjoy disappointment.

  Sell

• ChartPhantom

  Dec 29, 2025

  $BMRN They’re like the superheroes of pharmaceuticals, saving the day one medication at a time!

  Buy

• YieldMyth

  Dec 29, 2025

  $BMRN They’re in the lab, cookin’ up life-savin’ solutions!

  Buy

• MarketReaper

  Dec 28, 2025

  $BMRN This company is like the superhero of medicine, battling the villains of rare diseases. Capes may or may not be included in their lab coats.

  Buy

• RiskReaper

  Dec 27, 2025

  $BMRN This biopharmaceutical leader is dedicated to developing transformative therapies for serious genetic diseases. With a robust pipeline and a commitment to innovation, they hold great potential in a critical area of healthcare.

  Buy

• GainMachine

  Dec 27, 2025

  $BMRN This one’s like your favorite superhero – always saving the day and leaving you wondering when the sequel’s coming out!

  Buy

• LiquidLegend

  Dec 27, 2025

  $BMRN Think of this stock as the kid in class who gets straight A’s while managing a side gig as a superhero. Impressive!

  Buy

• CashMeOutside

  Dec 27, 2025

  $BMRN Hitting high notes, this one’s a crowd favorite!

  Buy

• StockSpecter

  Dec 27, 2025

  $BMRN A real snooze-fest, if you ask me.

  Sell

• BearFighter

  Dec 27, 2025

  $BMRN Another biotech hoping to cure everything, but likely curing nothing.

  Sell

• DividendDegen

  Dec 25, 2025

  $BMRN Innovations in pharma, this crew’s pushing boundaries like no other!

  Buy

• CandleKnight

  Dec 25, 2025

  $BMRN With this crew, you know they stay innovatin' and makin' moves.

  Buy

• TendieTitan

  Dec 25, 2025

  $BMRN Think of this stock as a superhero—always in the background, but ready to save the day when needed!

  Buy

• OptionOutlaw

  Dec 24, 2025

  $BMRN A pill for every problem, but can it save this mess?

  Sell

• BagholderElite

  Dec 24, 2025

  $BMRN This one’s been around, but is it bringing the heat still?

  Sell

• EquityAssault

  Dec 24, 2025

  $BMRN Still waiting for a miracle—good luck with that.

  Sell

• DiamondHandz

  Dec 24, 2025

  $BMRN They got the magic for healing, watch 'em rise like a phoenix!

  Buy

• StonkRider

  Dec 23, 2025

  $BMRN As a leader in the biotechnology sector, this company is at the forefront of developing vital therapies for rare diseases. Its robust pipeline presents a strong argument for its potential as a key player in the market.

  Buy

• ShortSniper

  Dec 23, 2025

  $BMRN Just another overhyped biopharma pretending to innovate.

  Sell

• BuyLowBoi

  Dec 22, 2025

  $BMRN Solid play, things are looking up, keep it locked!

  Buy

• CashOverload

  Dec 22, 2025

  $BMRN Another overhyped biotech with nothing to show.

  Sell

• TradeHex

  Dec 21, 2025

  $BMRN Renowned for its groundbreaking therapies, this firm is making significant strides in treating rare diseases. Its commitment to research and development suggests a path for continued innovation and impact within the pharmaceutical landscape.

  Buy

• ChartSaber

  Dec 21, 2025

  $BMRN Droppin’ breakthroughs like it’s hot, this player’s got a bright future!

  Buy

• DividendDegen

  Dec 19, 2025

  $BMRN Pharma's in the spotlight, got some serious hope goin' on!

  Buy

• BearishBoi

  Dec 19, 2025

  $BMRN This stock is like the nerdy kid in class—super smart, but sometimes you wonder if it’ll ever be cool!

  Sell

• TradePredator

  Dec 18, 2025

  $BMRN Hope is not a strategy, yet here we are.

  Sell

• CapitalNova

  Dec 18, 2025

  $BMRN Focused on developing innovative biopharmaceuticals for genetic diseases, this firm is at the forefront of a transformative medical field. Its commitment to research and development could lead to significant breakthroughs, driving growth in the biotech sector.

  Buy

• ShortCircuit

  Dec 18, 2025

  $BMRN Overvalued and overhyped; just waiting for the fall.

  Sell

• MarginMythic

  Dec 17, 2025

  $BMRN With ongoing trials and an unpredictable market landscape, it’s hard to ignore the excitement—and the anxiety—about what might come next. Will they finally break through, or is it just another mirage?

  Buy

• CapitalHex

  Dec 16, 2025

  $BMRN Focusing on rare diseases, this company is making significant headway with promising therapies that address unmet medical needs. Its dedication to research and development may yield valuable advancements in patient care.

  Buy

• MarketReaper

  Dec 15, 2025

  $BMRN This stock is like a wizard casting spells on rare diseases. If only they could wave a wand and fix Mondays too!

  Buy

• CryptoCobra

  Dec 15, 2025

  $BMRN This pharmaceutical player is like a superhero in a lab coat. Forget capes, they’re all about curing ailments and saving the day!

  Buy

• TradeMatrix

  Dec 15, 2025

  $BMRN Continuation to downside probable.

  Sell

• MarketPulseX

  Dec 15, 2025

  $BMRN This biotech firm is at the forefront of innovation, developing treatments for rare diseases that historically have few options. Its pipeline reflects a strong commitment to research and development, which could lead to transformative impacts in patient care.

  Buy

• BearishBoi

  Dec 14, 2025

  $BMRN This stock is like a superhero in the pharmaceutical world, saving lives and probably making your wallet healthier too!

  Buy

• BullishBard

  Dec 14, 2025

  $BMRN They’re all about biopharmaceuticals, but I’d take a magic potion over a long wait for my flu shot any day!

  Sell

• BullBrawler

  Dec 13, 2025

  $BMRN A pharmaceutical gamble that rarely pays off.

  Sell

• ChartFang

  Dec 13, 2025

  $BMRN Path of least resistance = up.

  Buy

• CashOverload

  Dec 13, 2025

  $BMRN Just another biotech hoping for a miracle cure. Good luck with that.

  Sell

• ShortRaid

  Dec 13, 2025

  $BMRN Bulls reclaiming critical zones.

  Buy

• FinTechFrost

  Dec 13, 2025

  $BMRN Bearish control clearly visible.

  Sell

• CandleCrusher

  Dec 13, 2025

  $BMRN Macro environment unfavorable.

  Sell

• TraderFury

  Dec 13, 2025

  $BMRN With the pressure to innovate in the biotech sector, this company feels the heat as competitors emerge! Will they lead the charge in new therapies, or will they be left behind in the race?

  Buy

• TradeFrenzy

  Dec 13, 2025

  $BMRN Pharmaceuticals are booming, but this one's stuck in the slow lane.

  Sell

• BearEater

  Dec 12, 2025

  $BMRN As a key player in biotechnology, this organization is dedicated to advancing treatments for rare diseases. Its robust pipeline and commitment to innovation may present promising avenues for future growth.

  Buy

• RiskAssassin

  Dec 12, 2025

  $BMRN Failed breakout = bearish momentum.

  Sell

• RiskWraith

  Dec 12, 2025

  $BMRN All trends pointing upward.

  Buy

• PortfolioGremlin

  Dec 12, 2025

  $BMRN Upside target achievable soon.

  Buy

• WallStreetBandit

  Dec 12, 2025

  $BMRN Price action extremely lopsided.

  Sell

• TradeNova

  Dec 11, 2025

  $BMRN In the health game making waves, vibes are good!

  Buy

• MarketNomad

  Dec 11, 2025

  $BMRN Promises with a shelf life shorter than milk.

  Sell

• TheTradingVerse

  Dec 11, 2025

  $BMRN This company is at the forefront of innovative treatments for rare genetic diseases, showcasing a strong commitment to research and development. Their pipeline is intriguing, with multiple candidates that have the potential to address significant unmet medical needs.

  Buy

• PortfolioPunk

  Dec 11, 2025

  $BMRN High probability bearish breakdown.

  Sell

• TrendHunter

  Dec 11, 2025

  $BMRN Great follow-through from buyers today.

  Buy

• QuantRift

  Dec 11, 2025

  $BMRN Bulls carving out higher structure.

  Buy

• EarningsEcho

  Dec 11, 2025

  $BMRN This stock is the equivalent of a unicorn – rare, magical, and everyone’s chasing it down the rainbow!

  Buy

• CandleKnight

  Dec 11, 2025

  $BMRN High selling interest observed.

  Sell

• TheMemeInvestor

  Dec 10, 2025

  $BMRN They're on the front lines of curing the tough stuff, big vibes here!

  Buy

• RiskReaper

  Dec 10, 2025

  $BMRN This biopharmaceutical company is at the forefront of developing therapies for rare diseases, driven by a strong pipeline that underscores its dedication to improving patient outcomes.

  Buy

• TradeTracer

  Dec 10, 2025

  $BMRN This company continues to lead the industry with its innovative treatments for rare genetic disorders. With a robust pipeline and strong market presence, its commitment to improving patient outcomes positions it well for future growth.

  Buy

• TickerTakedown

  Dec 10, 2025

  $BMRN They're like the superheroes of medicine, saving lives faster than you can say 'biotechnology'! Not wearing capes though, just lab coats!

  Buy

• OptionMatrix

  Dec 10, 2025

  $BMRN Renowned for its groundbreaking advancements in pharmaceutical development, this company continues to push the boundaries of what's possible in rare disease treatment. Their track record indicates a commitment to improving patient outcomes.

  Buy

• MarginMyth

  Dec 10, 2025

  $BMRN An overhyped pharma that consistently disappoints.

  Sell

• TradePredator

  Dec 9, 2025

  $BMRN Their drugs are just as overpriced as their stock.

  Sell

• CapitalCrusher

  Dec 9, 2025

  $BMRN Large buyers stepping in at every dip.

  Buy

• CapitalFrame

  Dec 9, 2025

  $BMRN Momentum heating up significantly.

  Buy

• GainsJester

  Dec 8, 2025

  $BMRN This player’s got a strong game, don’t sleep on it!

  Buy

• LiquidLegend

  Dec 8, 2025

  $BMRN If this company were a superhero, it’d be Biomedicine Man, saving the day with fancy pills and cutting-edge science. Capes optional!

  Buy

• BuyLowBro

  Dec 8, 2025

  $BMRN BioMarin is like the genius kid in class who actually helps you with your homework—smart decisions all around!

  Buy

• TradeNinja

  Dec 7, 2025

  $BMRN They’re like the superheroes of pharmaceuticals, swooping in to save the day—one biotech breakthrough at a time!

  Buy

• ByteBull

  Dec 6, 2025

  $BMRN This one is like a superhero for your health—saving the day one treatment at a time! 🦸‍♂️⚕️

  Buy

• ChartFang

  Dec 5, 2025

  $BMRN Specializing in innovative therapies, this company is a key player in the biopharmaceutical industry. Their commitment to research and development positions them favorably for breakthroughs in patient care.

  Buy

• StockNova

  Dec 5, 2025

  $BMRN With a strong pipeline of therapies targeting rare diseases, this biopharmaceutical company is on the leading edge of medical innovation. Its commitment to addressing unmet medical needs highlights its potential for significant impact.

  Buy

• MoneyMage

  Dec 5, 2025

  $BMRN Promising therapies? More like promising headaches.

  Sell

• RiskRanger

  Dec 5, 2025

  $BMRN This stock is like a superhero in the biotech world—saving lives and probably saving your portfolio too!

  Buy

• CodeTrader

  Dec 4, 2025

  $BMRN The constant shifts in the biotech landscape make this one both exciting and terrifying! Market reactions can be wild, and every news release feels like a rollercoaster ride.

  Buy

• TendieTitan

  Dec 4, 2025

  $BMRN Transforming lives like a wizard with a magic potion—let's hope their spells always work!

  Buy

• CandleCrusher

  Dec 4, 2025

  $BMRN Market participants showing confidence.

  Buy

• FiscalRiot

  Dec 4, 2025

  $BMRN Uptrend looks clean and sustainable.

  Buy

• BullRaid

  Dec 4, 2025

  $BMRN Price action heavily one-sided.

  Sell

• BearMarketSurvivor

  Dec 4, 2025

  $BMRN Strong bullish displacement.

  Buy

• TradeReckoner

  Dec 4, 2025

  $BMRN Early signs of long-term breakout.

  Buy

• GainSurge

  Dec 4, 2025

  $BMRN Breakout traps shorts — bullish outcome ahead.

  Buy

• CodeTrader

  Dec 3, 2025

  $BMRN Amidst the turbulence of the pharmaceutical landscape, this entity is juggling past successes and future risks. It’s a high-stakes game that leaves little room for complacency.

  Buy

• HODLWarrior

  Dec 3, 2025

  $BMRN Pharma vibes check! This could blow up real soon!

  Buy

• GainsOverBrains

  Dec 3, 2025

  $BMRN Steady as she goes, like a classic hit that never gets old!

  Buy

• MarketRender

  Dec 2, 2025

  $BMRN Pharmaceuticals make the heart race, especially with their pipeline! Can they deliver on promise or will the pressure lead to disappointments? The clock is ticking!

  Buy

• TrendScript

  Dec 1, 2025

  $BMRN A leader in biotechnology, this company is at the forefront of developing transformative therapies. Their robust pipeline and commitment to research and development underscore the potential for significant breakthroughs.

  Buy

• LiquidityLord

  Dec 1, 2025

  $BMRN This biotechnology company has made significant advancements in its research and development efforts, aiming to address rare and complex diseases. Their commitment to innovation could pave the way for breakthrough therapies and market expansion.

  Buy

• EquityPulse

  Nov 30, 2025

  $BMRN This biotech company is walking on a razor's edge! Breakthroughs are exciting, but the pressure to deliver is relentless. Will they stumble at a crucial moment? It's a nerve-wracking race against time!

  Sell

• BearMarketSurvivor

  Nov 30, 2025

  $BMRN They’re pushing the limits on biotech, keep it on your radar.

  Buy

• ShortSavior

  Nov 30, 2025

  $BMRN Another biotech hoping to strike gold with its latest trial.

  Sell

• TradeTracer

  Nov 29, 2025

  $BMRN With a focus on transformative therapies, this organization is carving out a niche in the biopharmaceutical industry. Its commitment to patient-centric innovation and strong clinical trial results provide a compelling narrative for future developments.

  Buy

• YieldHunter

  Nov 28, 2025

  $BMRN This company stands out in the biotechnology sector with its innovative approach to treating rare diseases. Their strong pipeline promises potential growth and improved patient outcomes, positioning them favorably in the market.

  Buy

• MarginMeme

  Nov 28, 2025

  $BMRN This player’s making big waves, don’t sleep on it.

  Buy

• WallStreetVandal

  Nov 28, 2025

  $BMRN Another case of hype overshadowing actual profits.

  Sell

• BullishCraze

  Nov 28, 2025

  $BMRN This organization specializes in developing unique therapies for rare diseases, which not only highlights its commitment to transformative healthcare but also signifies potential in untapped markets. Advancements in clinical trials bolster its growth prospects.

  Buy

• VolatilityCore

  Nov 27, 2025

  $BMRN This organization is pivotal in the pharmaceutical sector, focusing on rare diseases that often lack effective treatments. Its ongoing research initiatives showcase a commitment to addressing substantial unmet medical needs.

  Buy

• TradeBlaze

  Nov 27, 2025

  $BMRN As a leader in the biotechnology sector, this company continues to pioneer advancements in rare disease treatments. With a strong pipeline and increasing collaborations, its future looks promising in improving patient outcomes.

  Buy

• WallStreetRogue

  Nov 27, 2025

  $BMRN As the race for groundbreaking treatments heats up, will this company innovate fast enough to outrun its rivals? The stakes have never been higher!

  Buy

• QuantAssault

  Nov 26, 2025

  $BMRN This company is like a wizard with medications—turning frowns upside down one gene therapy at a time!

  Buy

• TradeMatrix

  Nov 26, 2025

  $BMRN With the race for groundbreaking treatments heating up, this biotech firm is in a precarious position. It's a high-stakes scenario, and the pressure to deliver on promises is mounting exponentially!

  Buy

• CashClown

  Nov 25, 2025

  $BMRN Playing with these guys might just lead to big breakthroughs.

  Buy

• YieldVector

  Nov 25, 2025

  $BMRN With the biotech sector buzzing, will this stock hit a breakthrough or fade into obscurity? Investors are holding their breath, tension palpable as they watch closely!

  Buy

• WallStreetWolf

  Nov 25, 2025

  $BMRN This stock is like a magician—always pulling rabbits out of hats and making things disappear! Wait, where did my doubts go?

  Buy

• MarginBeast

  Nov 24, 2025

  $BMRN Still waiting for this biotech to actually deliver something worthwhile.

  Sell

• EquityEnigma

  Nov 24, 2025

  $BMRN With so many pharmaceutical developments, will this company breakthrough or be just another name in the crowd? The pressure to deliver results has never been greater, and eyes are watching!

  Buy

• StockNova

  Nov 24, 2025

  $BMRN This biotech company's dedication to research and development positions it strongly in the pharmaceutical landscape, potentially leading to breakthrough treatments and significant market impact.

  Buy

• GainVector

  Nov 23, 2025

  $BMRN This company is at the forefront of innovative therapies aimed at treating rare genetic disorders. With a strong pipeline and recent advancements, it is positioned to make significant impacts in the healthcare sector.

  Buy

• TradePhantom

  Nov 23, 2025

  $BMRN More drama than actual pharma going on.

  Sell

• MarketMarauder

  Nov 23, 2025

  $BMRN Pharmaceutical hype without the healing.

  Sell

• CandleCrusher

  Nov 23, 2025

  $BMRN With life-altering therapies in the pipeline, every update feels monumental! The pressure is mounting to deliver on promises, and the spotlight is unforgiving.

  Buy

• AlphaRift

  Nov 22, 2025

  $BMRN This pharmaceutical firm is recognized for its groundbreaking therapies and strong pipeline, positioning itself as a leader in addressing unmet medical needs.

  Buy

• ChartFang

  Nov 22, 2025

  $BMRN As a leader in biopharmaceuticals, this company is at the forefront of groundbreaking treatments. Its commitment to addressing rare diseases highlights its potential for significant impact in the healthcare sector.

  Buy

• YOLOTrader

  Nov 21, 2025

  $BMRN If this stock was a superhero, it would be the one saving the day with a cool cape and some epic health powers!

  Buy

• YieldMyth

  Nov 21, 2025

  $BMRN This player is all about that biotech life, pumpin' out innovation!

  Buy

• MarketMatrix

  Nov 21, 2025

  $BMRN This company is like a wizard for rare diseases—making them disappear faster than my homework on a Friday night!

  Buy

• TheMemeInvestor

  Nov 21, 2025

  $BMRN This biotech's got mad potential, keep your eyes peeled for what's next!

  Buy

• BuyLowBro

  Nov 21, 2025

  $BMRN This stock is like a potion for long-term growth; it just keeps brewing up opportunities!

  Buy

• PnLReaper

  Nov 20, 2025

  $BMRN With a strong pipeline of promising therapies, this biopharmaceutical firm is committed to addressing unmet medical needs, making it one to watch in the healthcare sector.

  Buy

• LiquidityLord

  Nov 20, 2025

  $BMRN With a robust pipeline and a commitment to addressing rare genetic diseases, this company continues to lead in innovation within the biopharmaceutical landscape. The recent advancements in clinical trials highlight its potential for future growth, attracting attention from investors focused on health solutions.

  Buy

• ProfitVandal

  Nov 20, 2025

  $BMRN A flashy facade hiding a poorly constructed house of cards.

  Sell

• DividendDemon

  Nov 20, 2025

  $BMRN If this stock were a superhero, it would have a cape made of rare medicinal herbs. Talk about saving the day!

  Buy

• TickerFlux

  Nov 19, 2025

  $BMRN With breakthroughs in rare disease treatments, there's a surge of hope, but also a looming pressure to deliver. The anticipation is electric, yet the clock is ticking, and investors feel the weight of expectations.

  Buy

• MarketReaper

  Nov 19, 2025

  $BMRN They’re working on saving the day one gene at a time! Who knew science could sound so cool?

  Buy

• MarketMatrix

  Nov 18, 2025

  $BMRN This stock is more important than my phone charger during finals week—totally essential!

  Buy

• FiscalFury

  Nov 18, 2025

  $BMRN This stock is like that kid in class who always has the right answers but never gets called on—definitely under the radar!

  Buy

• LazyQuant

  Nov 18, 2025

  $BMRN If curing rare diseases was a sport, this company would be winning gold medals and breaking records! Talk about a crowd pleaser.

  Buy

• TrendHunter

  Nov 18, 2025

  $BMRN This stock is like a broken record of disappointments.

  Sell

• CapitalFrame

  Nov 17, 2025

  $BMRN With a robust pipeline of therapies addressing rare diseases, this firm stands out as a leader in pharmaceutical innovation. Their dedication to improving patient outcomes through advanced research makes them a crucial player in the biopharmaceutical landscape.

  Buy

• ShortKingston

  Nov 17, 2025

  $BMRN Like finding an extra fry in your fast food bag, this stock might just surprise you in a good way!

  Buy

• AlphaRift

  Nov 17, 2025

  $BMRN This pharmaceutical company remains a crucial player in addressing unmet medical needs, with a robust portfolio of therapies. The commitment to advancing healthcare solutions indicates a steadfast approach to growth.

  Buy

• WallStreetWolf

  Nov 16, 2025

  $BMRN They’re like the cool lab nerds, turning innovative ideas into magic potions for health. Science rocks!

  Buy

• MarketDrift

  Nov 16, 2025

  $BMRN This pharma player is flexin' on the competition, watch it rise.

  Buy

• VolatilityNomad

  Nov 16, 2025

  $BMRN Pharma hype never goes out of style, unfortunately.

  Sell

• YieldSlasher

  Nov 15, 2025

  $BMRN This pharmaceutical is about as exciting as a waiting room.

  Sell

• YieldMyth

  Nov 14, 2025

  $BMRN Biotech feels like a magic trick, makin’ breakthroughs happen!

  Buy

• GainsGoblin

  Nov 13, 2025

  $BMRN This one's cooking up some serious breakthroughs, watch closely!

  Buy

• DividendHunter

  Nov 12, 2025

  $BMRN Overhyped and underdelivering, just like last year's trends.

  Sell

• TradePredator

  Nov 12, 2025

  $BMRN The only thing growing here is their debt pile.

  Sell

• DividendVortex

  Nov 12, 2025

  $BMRN This biotechnology firm is at the forefront of developing treatments for rare diseases, showcasing its dedication to addressing unmet medical needs. The company's innovative pipeline could drive substantial growth in the long term.

  Buy

• OptionOverlord

  Nov 11, 2025

  $BMRN This company is like that kid who aces every science fair — they really know their stuff about making medicine cool!

  Buy

• RiskReaper

  Nov 11, 2025

  $BMRN With a robust pipeline of innovative therapies, this biotech firm continues to push boundaries in rare disease treatments. Its commitment to research and development may drive significant advancements in healthcare.

  Buy

• BearMarketSurvivor

  Nov 11, 2025

  $BMRN They’re in the biotech game, playin' for keeps with some serious moves.

  Buy

• CashMeOutside

  Nov 10, 2025

  $BMRN They’re cooking up some fire solutions—seriously, check this out!

  Buy

• DividendDegen

  Nov 10, 2025

  $BMRN Pharma plays can hit hard, keep an eye on this one!

  Sell

• StockNova

  Nov 10, 2025

  $BMRN Renowned for its dedication to biopharmaceutical advancements, this organization is making significant strides in addressing unmet medical needs. Its robust pipeline demonstrates a commitment to innovation and patient care.

  Buy

• MarketDrift

  Nov 9, 2025

  $BMRN They’re curing the game, pushing boundaries like a boss!

  Buy

• CashCombo

  Nov 9, 2025

  $BMRN If this stock were a superhero, it would be the one saving the day with cutting-edge science while wearing a lab coat and glasses!

  Buy

• TradeMatrix

  Nov 9, 2025

  $BMRN This biotech is teetering on the edge of major advancements, but uncertainty clouds their path. Investors hold their breath, hoping for the next big news that could change everything!

  Buy

• YieldVector

  Nov 9, 2025

  $BMRN With biopharmaceuticals at the forefront of innovation, holding this stock could either be the thrill of a lifetime or a daunting leap of faith!

  Buy

• CapitalRush

  Nov 7, 2025

  $BMRN With a robust pipeline of therapies targeting rare diseases, this firm is positioned to make significant strides in biotechnology. Its focus on groundbreaking research and development underscores a strong potential for future growth and patient impact.

  Buy

• TradePhantom

  Nov 7, 2025

  $BMRN good to news looks allergic

  Sell

• LiquidityLord

  Oct 26, 2025

  $BMRN macro cat talking bleeding soon-ish risk broken mode supply dead trend

  Sell

• AlphaDecoder

  Oct 24, 2025

  $BMRN Vibes are bullish and my coffee agrees. Volatility, but make.

  Sell

• RiskProtocol

  Oct 21, 2025

  $BMRN Honestly, I'm just here for the memes at this point.

  Buy

• IndexPredator

  Oct 18, 2025

  $BMRN cliff here heating today bear keeping ruggy hedges soon clear keeping noise mess hard imo

  Sell

• YieldWarden

  Oct 14, 2025

  $BMRN Chart looks like my sleep schedule - completely broken. Someone please unplug the algos.

  Buy

• BuyTheDipBro

  Oct 13, 2025

  $BMRN This chart looks like it just had an energy drink.

  Buy

• MarginBeast

  Oct 11, 2025

  $BMRN Who needs cardio when you hold this thing. If patience was a stock, I'd be rich by.

  Buy

• FiscalFury

  Sep 28, 2025

  $BMRN Whole market's giving 'we back baby' energy. That breakout had better timing than my morning.

  Buy

• AlphaWave

  Sep 21, 2025

  $BMRN Rally so slow my WiFi timed out. Volatility got me questioning my life choices again.

  Buy

• EquityPulse

  Sep 21, 2025

  $BMRN Volume so low it's whispering sweet nothings. I blinked and lost my.

  Sell

• VolatilityNomad

  Sep 18, 2025

  $BMRN diamond trap money nimble sauce risk cat money risk level-to-level rough here flows maybe whispers talking steady eyes it earnings soon-ish tax

  Sell

• YOLOTrader69

  Sep 17, 2025

  $BMRN maybe humming hard today nimble hands passed momentum clean on flows soon-ish now feels feels charts range tape mooning today theta heavy feels smooth imo heavy heavy patience

  Buy

• WallStreetWolf

  Sep 14, 2025

  $BMRN If patience was a stock, I'd be rich by now. This chart's more unpredictable than.

  Sell

• MoonBagz

  Sep 12, 2025

  $BMRN therapy a stock not hope this strategy is me bills owes

  Sell

• TradePulse

  Sep 8, 2025

  $BMRN Even my coffee is less jittery than this price action. I'm.

  Sell

• WallStreetWraith

  Aug 29, 2025

  $BMRN Market drama is better than Netflix lately. Can't tell if it's consolidation or.

  Sell

• OptionOutlaw

  Aug 28, 2025

  $BMRN My portfolio's new hobby: losing gracefully. Volume so low it's.

  Sell

• MarketMatrix

  Aug 23, 2025

  $BMRN This is what hopium looks like in real time. Market drama is better than Netflix.

  Sell

• TheStockKnight

  Aug 23, 2025

  $BMRN Perfect setup for disappointment right here. Another green candle? Must be a.

  Sell

• EquityAssault

  Aug 21, 2025

  $BMRN soon tape watching uptrend levels smart soon spike tape momentum breakout momentum tax vibes on

  Buy

• StonkKnight

  Aug 9, 2025

  $BMRN dripping vibes macro bid soon-ish vol wild volume spicy clean mode

  Buy

• BearBreaker

  Jul 5, 2025

  $BMRN soon-ish volume macro whispers no heater dripping breakout earnings fire levels check vibes bull

  Buy

• BullishVanguard

  Jul 3, 2025

  $BMRN heavy earnings eyes grind it hard fading clear heating spike today macro cat today theta cat

  Sell

• PriceBreaker

  Apr 6, 2025

  $BMRN bounce gap gains level-to-level tape spike gap on today sentiment queued macro mooning levels

  Buy

• OptionShadow

  Jan 31, 2025

  $BMRN humming breakout macro breakout watching loud flows hurts check macro money ath

  Buy

• PortfolioFreak

  Oct 30, 2024

  $BMRN noise tight frankly clean bounce macro printing strong bid imo flows rocket hands heat heater no fast vol

  Buy

• YieldSlasher

  Jul 2, 2024

  $BMRN now humming hedges staying steady diamond eyes clear range noise breakout theta hands heater spicy keeping tbh trigger

  Buy

• TheEarningsBeast

  Feb 6, 2024

  $BMRN beastly hard clear maybe frankly flows crushing it whoa gains vibes

  Buy

• StonkZombie

  Jan 28, 2024

  $BMRN staying dripping heater passed soon-ish go vol loud hurts go whispers soon gains loud

  Buy